Severe bleeding complication of low molecular weight heparin in a dialysis patient with deep venous thrombosis

Hao Hsi Kao, Mai Szu Wu, Ching Wei Hsu, Hui Chun Lu, Bor Yiing Jiang

Research output: Contribution to journalArticle

Abstract

Low-molecular-weight heparin (LMWH), a mixture of polysaccharide molecules, is derived from unfractionated heparin (UFH) by physical and/or chemical processes. Using subcutaneous injections of LMWH to treat patients with deep vein thrombosis has several major advantages over the use of conventional intravenous or subcutaneous UFH therapy. For instance, there is no requirement for laboratory monitoring of activated partial thromboplastin time with LMWH. However, in the report we observed a 65-year-old female with end-stage renal disease and found that she, after receiving anticoagulant treatment with Nadroparin (LMWH), developed bleeding complications. It indicates that the potential bleeding adverse effect of LMWHs should be taken into account when applied to patients with severe renal disease.

Original languageEnglish
Pages (from-to)140-145
Number of pages6
JournalJournal of Internal Medicine of Taiwan
Volume18
Issue number3
Publication statusPublished - Jun 2007
Externally publishedYes

Fingerprint

Low Molecular Weight Heparin
Venous Thrombosis
Dialysis
Hemorrhage
Heparin
Chemical Phenomena
Nadroparin
Physical Phenomena
Partial Thromboplastin Time
Subcutaneous Injections
Anticoagulants
Chronic Kidney Failure
Polysaccharides
Kidney
Therapeutics

Keywords

  • Complication
  • Hemodialysis
  • Low molecular weight heparin

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Severe bleeding complication of low molecular weight heparin in a dialysis patient with deep venous thrombosis. / Kao, Hao Hsi; Wu, Mai Szu; Hsu, Ching Wei; Lu, Hui Chun; Jiang, Bor Yiing.

In: Journal of Internal Medicine of Taiwan, Vol. 18, No. 3, 06.2007, p. 140-145.

Research output: Contribution to journalArticle

Kao, Hao Hsi ; Wu, Mai Szu ; Hsu, Ching Wei ; Lu, Hui Chun ; Jiang, Bor Yiing. / Severe bleeding complication of low molecular weight heparin in a dialysis patient with deep venous thrombosis. In: Journal of Internal Medicine of Taiwan. 2007 ; Vol. 18, No. 3. pp. 140-145.
@article{312cfa76b81348298ac9614b01bba9f6,
title = "Severe bleeding complication of low molecular weight heparin in a dialysis patient with deep venous thrombosis",
abstract = "Low-molecular-weight heparin (LMWH), a mixture of polysaccharide molecules, is derived from unfractionated heparin (UFH) by physical and/or chemical processes. Using subcutaneous injections of LMWH to treat patients with deep vein thrombosis has several major advantages over the use of conventional intravenous or subcutaneous UFH therapy. For instance, there is no requirement for laboratory monitoring of activated partial thromboplastin time with LMWH. However, in the report we observed a 65-year-old female with end-stage renal disease and found that she, after receiving anticoagulant treatment with Nadroparin (LMWH), developed bleeding complications. It indicates that the potential bleeding adverse effect of LMWHs should be taken into account when applied to patients with severe renal disease.",
keywords = "Complication, Hemodialysis, Low molecular weight heparin",
author = "Kao, {Hao Hsi} and Wu, {Mai Szu} and Hsu, {Ching Wei} and Lu, {Hui Chun} and Jiang, {Bor Yiing}",
year = "2007",
month = "6",
language = "English",
volume = "18",
pages = "140--145",
journal = "Journal of Internal Medicine of Taiwan",
issn = "1016-7390",
publisher = "臺灣內科醫學會",
number = "3",

}

TY - JOUR

T1 - Severe bleeding complication of low molecular weight heparin in a dialysis patient with deep venous thrombosis

AU - Kao, Hao Hsi

AU - Wu, Mai Szu

AU - Hsu, Ching Wei

AU - Lu, Hui Chun

AU - Jiang, Bor Yiing

PY - 2007/6

Y1 - 2007/6

N2 - Low-molecular-weight heparin (LMWH), a mixture of polysaccharide molecules, is derived from unfractionated heparin (UFH) by physical and/or chemical processes. Using subcutaneous injections of LMWH to treat patients with deep vein thrombosis has several major advantages over the use of conventional intravenous or subcutaneous UFH therapy. For instance, there is no requirement for laboratory monitoring of activated partial thromboplastin time with LMWH. However, in the report we observed a 65-year-old female with end-stage renal disease and found that she, after receiving anticoagulant treatment with Nadroparin (LMWH), developed bleeding complications. It indicates that the potential bleeding adverse effect of LMWHs should be taken into account when applied to patients with severe renal disease.

AB - Low-molecular-weight heparin (LMWH), a mixture of polysaccharide molecules, is derived from unfractionated heparin (UFH) by physical and/or chemical processes. Using subcutaneous injections of LMWH to treat patients with deep vein thrombosis has several major advantages over the use of conventional intravenous or subcutaneous UFH therapy. For instance, there is no requirement for laboratory monitoring of activated partial thromboplastin time with LMWH. However, in the report we observed a 65-year-old female with end-stage renal disease and found that she, after receiving anticoagulant treatment with Nadroparin (LMWH), developed bleeding complications. It indicates that the potential bleeding adverse effect of LMWHs should be taken into account when applied to patients with severe renal disease.

KW - Complication

KW - Hemodialysis

KW - Low molecular weight heparin

UR - http://www.scopus.com/inward/record.url?scp=34447340626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447340626&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:34447340626

VL - 18

SP - 140

EP - 145

JO - Journal of Internal Medicine of Taiwan

JF - Journal of Internal Medicine of Taiwan

SN - 1016-7390

IS - 3

ER -